Mallinckrodt public limited company (MNK)
(Delayed Data from NYSE)
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Mallinckrodt (MNK) Q2 Earnings Beat Estimates
by Zacks Equity Research
Mallinckrodt (MNK) delivered earnings and revenue surprises of 20.48% and -0.05%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Mallinckrodt (MNK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Mallinckrodt (MNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel
by Zacks Equity Research
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mallinckrodt (MNK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Mallinckrodt (MNK) closed the most recent trading day at $9.18, moving +1.89% from the previous trading session.
Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
by Zacks Equity Research
Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
Mallinckrodt Down After Agreement with DOJ for Litigation
by Zacks Equity Research
Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.
Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cara Shares Up on Positive Phase III Data for Itchiness Drug
by Zacks Equity Research
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down
by Zacks Equity Research
Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.
Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS
by Zacks Equity Research
Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.
Mallinckrodt Ends Enrollment in Phase III for Terlipressin
by Zacks Equity Research
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View
by Zacks Equity Research
Mallinckrodt (MNK) earnings and sales surpass estimates in the first quarter, which led to an increase in annual guidance.
Mallinckrodt (MNK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Mallinckrodt (MNK) delivered earnings and revenue surprises of 12.14% and 2.47%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.
Mallinckrodt (MNK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Mallinckrodt (MNK) closed at $15.29, marking a -1.1% move from the previous day.
Mallinckrodt (MNK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Mallinckrodt (MNK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Bausch Health (BHC) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
MNK or AMPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MNK vs. AMPH: Which Stock Is the Better Value Option?
Mallinckrodt (MNK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Mallinckrodt (MNK) closed the most recent trading day at $21.66, moving -0.18% from the previous trading session.
Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Mallinckrodt (MNK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
by Zacks Equity Research
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
by Zacks Equity Research
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Zacks Value Trader Highlights: G-III Apparel, General Motors, Legg Mason, Mallinckrodt and United Natural Foods
by Zacks Equity Research
Zacks Value Trader Highlights: G-III Apparel, General Motors, Legg Mason, Mallinckrodt and United Natural Foods